Moneycontrol PRO

Sun Pharma: Ilumya illuminates

The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms

August 02, 2021 / 10:13 AM IST
Sun Pharma: Ilumya illuminates

Representative image

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Sun Pharma, India’s largest pharma company, (CMP: Rs 774, Market Cap: Rs 1,85,697 crore) appears to be doing well on the specialty products front, particularly as the re-opening of the US economy facilitates new products & clinical trials. Sales of specialty products during the reporting quarter, clocked $148 million  against $139 million in Q4 FY21 and $78 million in Q1 FY21. Growth was supported by traction for the Ilumya and the Cequa, used to treat plaque psoriasis and dry-eye disease...

  • PRO Panorama

    Moneycontrol Pro Panorama | A question mark hangs over the outlook for steel-makers

    Sep 27, 2021 / 03:15 PM IST

    In today’s Moneycontrol Pro Panorama: The Eastern Window, litmus test for Zee, IndiGo has the edge, Monsoon Watch, the VST Tillers CEO interview, Evergrande and the retail investor, and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Perfect storm over China

    Sep 18, 2021 / 10:34 AM IST

    From the Evergrande debt crisis to a slowing growth rate to the crackdown on technology companies to the growing confrontation with the West, the cup of woes is spilling over for China

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers